

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Tuesday, April 26, 2005

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L16	L15 and (HPMCAS or HPMCP or PVP! or CAT! or CAP! or HPMC)	14
<input type="checkbox"/>	L15	L14 and CETP	92
<input type="checkbox"/>	L14	\$200trifluoro-2-propanol	213
<input type="checkbox"/>	L13	L12 and L9	55
<input type="checkbox"/>	L12	HDL with hypertension	517
<input type="checkbox"/>	L11	HDL with hypertention	0
<input type="checkbox"/>	L10	L9 and L5	24
<input type="checkbox"/>	L9	CETP! or (cholesteryl ester transfer protein inhibitor)	1141
<input type="checkbox"/>	L8	L7 and transfer	41
<input type="checkbox"/>	L7	L6 and L5	82
<input type="checkbox"/>	L6	cholesterol	63665
<input type="checkbox"/>	L5	efonidipine	163
<input type="checkbox"/>	L4	nz-105	9
		<i>DB=USPT; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L3	nz-105	4
<input type="checkbox"/>	L2	concentration adj enhancing adj polymer	1
		<i>DB=PGPB; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L1	20030186952.pn.	1

END OF SEARCH HISTORY

Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#)
[Generate OACS](#)

Search Results - Record(s) 1 through 14 of 14 returned.

☐ 1. Document ID: US 20050038007 A1

Using default format because multiple data bases are involved.

L17: Entry 1 of 14

File: PGPB

Feb 17, 2005

PGPUB-DOCUMENT-NUMBER: 20050038007

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050038007 A1

TITLE: Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors

PUBLICATION-DATE: February 17, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Curatolo, William J.	Niantic	CT	US	
Friesen, Dwayne T.	Bend	OR	US	
Sutton, Steven C.	Niantic	CT	US	

US-CL-CURRENT: [514/171](#); [514/423](#), [514/460](#), [514/548](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 2. Document ID: US 20050031693 A1

L17: Entry 2 of 14

File: PGPB

Feb 10, 2005

PGPUB-DOCUMENT-NUMBER: 20050031693

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050031693 A1

TITLE: Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials

PUBLICATION-DATE: February 10, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Babcock, Walter C.	Bend	OR	US	
Friesen, Dwayne T.	Bend	OR	US	
Shanker, Ravi M.	Groton	CT	US	

Smithey, Daniel T.

Bend

OR

US

US-CL-CURRENT: 424/486

ABSTRACT:

A pharmaceutical composition comprises a solid adsorbate comprising a drug adsorbed onto a substrate and a lipophilic microphase-forming material. The solid adsorbate may also be co-administered with a lipophilic microphase-forming material to an in vivo use environment. The compositions of the present invention enhance the concentration of drug in a use environment.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20040197398 A1

L17: Entry 3 of 14

File: PGPB

Oct 7, 2004

PGPUB-DOCUMENT-NUMBER: 20040197398

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040197398 A1

TITLE: Dosage forms comprising a CETP inhibitors and an HMG-CoA reductase inhibitor

PUBLICATION-DATE: October 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Friesen, Dwayne T.	Bend	OR	US	
Lyon, David K.	Bend	OR	US	
Lorenz, Douglas A.	Bend	OR	US	
Hancock, Bruno C.	North Stonington	CT	US	
McDermott, Timothy J.	Salem	CT	US	
Shanker, Ravi M.	Groton	CT	US	

US-CL-CURRENT: 424/464

ABSTRACT:

A dosage form comprises (1) a solid amorphous dispersion comprising a cholesterol ester transfer protein inhibitor and an acidic concentration-enhancing polymer and (2) an HMG-CoA reductase inhibitor. The solid amorphous dispersion and the HMG-CoA reductase inhibitor are combined in the dosage form so that the solid amorphous dispersion and the HMG-CoA reductase inhibitor are substantially separate from one another in the dosage form.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 20040185102 A1

L17: Entry 4 of 14

File: PGPB

Sep 23, 2004

PGPUB-DOCUMENT-NUMBER: 20040185102
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040185102 A1

TITLE: Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor

PUBLICATION-DATE: September 23, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Friesen, Dwayne T.	Bend	OR	US	
Lyon, David K.	Bend	OR	US	
Lorenz, Douglas A.	Bend	OR	US	
Ketner, Rodney J.	Bend	OR	US	
Hancock, Bruno C.	North Stonington	CT	US	
McDermott, Timothy J.	Salem	CT	US	
Shanker, Ravi M.	Groton	CT	US	

US-CL-CURRENT: 424/486; 424/488, 514/423, 514/460, 514/548

ABSTRACT:

A dosage form comprises (1) a solid amorphous dispersion comprising a cholesteryl ester transfer protein inhibitor and a neutral or neutralized acidic polymer and (2) an HMG-CoA reductase inhibitor. The dosage form provides improved chemical stability of the HMG-CoA reductase inhibitor.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EOAC	Grand Cl
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 5. Document ID: US 20040132771 A1

L17: Entry 5 of 14

File: PGPB

Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132771
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040132771 A1

TITLE: Compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Babcock, Walter C.	Bend	OR	US	
Friesen, Dwayne T.	Bend	OR	US	
Shankar, Ravi M.	Groton	CT	US	

Smithey, Daniel T.

Bend

OR

US

US-CL-CURRENT: 514/311; 424/486

ABSTRACT:

A composition comprises (1) a solid amorphous adsorbate comprising a cholesteryl ester transfer protein (CETP) inhibitor and a substrate; and (2) an HMG-CoA reductase inhibitor. The solid amorphous adsorbate provides concentration enhancement of the CETP inhibitor relative to a control composition consisting essentially of the unadsorbed CETP inhibitor alone, resulting in improved bioavailability.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 6. Document ID: US 20030198674 A1

L17: Entry 6 of 14

File: PGPB

Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030198674

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030198674 A1

TITLE: Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Curatolo, William J.	Niantic	CT	US	
Sutton, Steven C.	Niantic	CT	US	
Appel, Leah E.	Bend	OR	US	

US-CL-CURRENT: 424/468

ABSTRACT:

The present invention relates to controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor, (CETPI) methods of using and methods of making same. In particular, it relates to a controlled release form of the CETPI [2R,4S] 4-[(3,5-bis-trifluoromethyl-- benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-qu- inoline-1-carboxylic acid ethyl ester.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 7. Document ID: US 20030186952 A1

L17: Entry 7 of 14

File: PGPB

Oct 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030186952
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030186952 A1

TITLE: Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors

PUBLICATION-DATE: October 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Crew, Marshall D.	Bend	OR	US	
Curatolo, William J.	Niantic	CT	US	
Friesen, Dwayne T.	Bend	OR	US	
Gumkowski, Michael Jon	Old Lyme	CT	US	
Lorenz, Douglas A.	Bend	OR	US	
Nightingale, James A. S.	Bend	OR	US	
Ruggeri, Roger B.	Waterford	CT	US	
Shanker, Ravi M.	Groton	CT	US	

US-CL-CURRENT: 514/177; 264/5

ABSTRACT:

A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Drawings	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	----------	----------

☐ 8. Document ID: US 20030170309 A1

L17: Entry 8 of 14

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170309
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030170309 A1

TITLE: Pharmaceutical compositions containing polymer and drug assemblies

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Babcock, Walter C.	Bend	OR	US	
Crew, Marshall D.	Bend	OR	US	
Friesen, Dwayne T.	Bend	OR	US	
Rabenstein, Mark D.	Bend	OR	US	
Shanker, Ravi M.	Groton	CT	US	
Smithey, Daniel T.	Bend	OR	US	

US-CL-CURRENT: 424/486

ABSTRACT:

Solutions containing polymer/drug assemblies of a low-solubility drug and polymer are disclosed. In addition, solid aggregated polymer/drug assemblies are disclosed comprising a low-solubility drug and polymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	DOC	Draw D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	---------

☐ 9. Document ID: US 20030104063 A1

L17: Entry 9 of 14

File: PGPB

Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030104063

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030104063 A1

TITLE: Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Babcock, Walter C.	Bend	OR	US	
Curatolo, William J.	Niantic	CT	US	
Friesen, Dwayne T.	Bend	OR	US	
Ketner, Rodney J.	Bend	OR	US	
Lo, Julian B.	Old Lyme	CT	US	
Nightingale, James A. S.	Bend	OR	US	
Shanker, Ravi M.	Groton	CT	US	
West, James B.	Bend	OR	US	

US-CL-CURRENT: 424/486

ABSTRACT:

A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	DOC	Draw D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	---------

☐ 10. Document ID: US 20030091643 A1

L17: Entry 10 of 14

File: PGPB

May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030091643
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030091643 A1

TITLE: Pharmaceutical compositions of dispersions of drugs and neutral polymers

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Friesen, Dwayne T.	Bend	OR	US	
Gumkowski, Michael J.	Old Lyme	CT	US	
Ketner, Rodney J.	Bend	OR	US	
Lorenz, Douglas A.	Bend	OR	US	
Nightingale, James A. S.	Bend	OR	US	
Shanker, Ravi M.	Groton	CT	US	
West, James B.	Bend	OR	US	

US-CL-CURRENT: 424/486; 514/249, 514/27, 514/29, 514/338, 514/575

ABSTRACT:

In one aspect, pharmaceutical compositions comprising dispersions of an acid-sensitive drug and a neutral dispersion polymer are disclosed. The acid-sensitive drug has improved chemical stability relative to dispersions of the drug and acidic polymers. In another aspect, pharmaceutical compositions of low-solubility drugs and amphiphilic, hydroxy-functional vinyl copolymers are disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 11. Document ID: US 20030072801 A1

L17: Entry 11 of 14

File: PGPB

Apr 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030072801
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030072801 A1

TITLE: Pharmaceutical compositions comprising drug and concentration-enhancing polymers

PUBLICATION-DATE: April 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Curatolo, William J.	Niantic	CT	US	
Friesen, Dwayne T.	Bend	OR	US	

US-CL-CURRENT: 424/465; 514/58

ABSTRACT:

A solubility-improved drug form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same drug form without the concentration-enhancing polymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	DOC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 12. Document ID: US 20030054038 A1

L17: Entry 12 of 14

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054038

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030054038 A1

TITLE: Pharmaceutical compositions of drugs and neutralized acidic polymers

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Crew, Marshall D.	Bend	OR	US	
Friesen, Dwayne T.	Bend	OR	US	
Ketner, Rodney J.	Bend	OR	US	
Shanker, Ravi M.	Groton	CT	US	
West, James B.	Bend	OR	US	

US-CL-CURRENT: 424/486

ABSTRACT:

Pharmaceutical compositions comprised of low-solubility and/or acid-sensitive drugs and neutralized acidic polymers are disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	DOC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 13. Document ID: US 20030054037 A1

L17: Entry 13 of 14

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054037

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030054037 A1

TITLE: Pharmaceutical compositions of adsorbates of amorphous drug

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Babcock, Walter C.	Bend	OR	US	
Friesen, Dwayne T.	Bend	OR	US	
Shanker, Ravi M.	Groton	CT	US	
Smithey, Daniel T.	Bend	OR	US	
Tadday, Ralph	Bend	OR	US	

US-CL-CURRENT: 424/486

ABSTRACT:

Pharmaceutical compositions comprise a low-solubility drug adsorbed onto a high surface area substrate to form an adsorbate. The compositions in some embodiments include a concentration-enhancing polymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Index	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-------	----------

☐ 14. Document ID: US 20030022944 A1

L17: Entry 14 of 14

File: PGPB

Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030022944

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030022944 A1

TITLE: Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gumkowski, Michael J.	Old Lyme	CT	US	
Franco, Lombardo	Gales Ferry	CT	US	
Murdande, Sharad B.	Waterford	CT	US	
Perlman, Michael E.	Old Saybrook	CT	US	

US-CL-CURRENT: 514/786

ABSTRACT:

CETP Inhibitors have improved solubility and bioavailability in a lipophilic vehicle comprising a digestible oil, a lipophilic solvent, or a surfactant. Preferred such compositions are self-emulsifying or self-microemulsifying, and comprise

1. a CETP inhibitor;
2. a cosolvent;

3. a surfactant having an HLB of 1 to 8;
4. a surfactant having an HLB of over 8 to 20; and
5. optionally, a digestible oil.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	IPC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Term	Documents
HPMCAS	265
HPMCA	1
HPMCP	588
HPMCPS	1
PVP	20117
CAT	144619
CAP	782152
HPMC	4989
HPMCS	86
(16 AND (((HPMCAS OR HPMCP OR HPMC) OR (PVP!)) OR (CAT!)) OR (CAP!))).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	14
(L16 AND (HPMCAS OR HPMCP OR PVP! OR CAT! OR CAP! OR HPMC)).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	14

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)



MEDLINE®

This Document**► Abstract-MEDLINE****Actions**

- [Cited By](#)
- [Save as Citation Alert](#)
- [E-mail Article](#)
- [Export Citation](#)

Effect of efonidipine hydrochloride (NZ-105) on modification of low density lipoprotein induced by rat cultured endothelial cells**Ito, S; Higashino, R; Tanaka, T; Takei, M; Kurimoto, T; Matsuda, K**

Central Research Laboratories, ZERIA Pharmaceutical Co., Ltd., Saitama, Japan

Abstract

We studied the effects of efonidipine hydrochloride [NZ-105: (+/-)-2-[benzyl (phenyl) amino] ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorina n-2-yl)-4-(3-nitro-phenyl)-3-pyridinecarboxylate hydrochloride ethanol] and nisoldipine on endothelial cell-induced low density lipoprotein (LDL) modification. The modification of LDL by cultured rat endothelial cells was performed by incubating 3 micrograms protein/well LDL with 5 microM CuSO₄ for 24 hr at 37 degrees C in the presence of confluent cells. The extent of modification was assayed by measuring the thiobarbituric acid-reactive substances (TBARS). Efonidipine hydrochloride reduced the TBARS level in a dose-dependent manner. At 3 x 10⁽⁻⁷⁾ M, efonidipine hydrochloride showed a significant effect. On the other hand, the significant effect of nisoldipine was observed only at 10⁽⁻⁵⁾ M. Thus the action of efonidipine hydrochloride on the inhibition of LDL-modification was much more potent than that of nisoldipine. As the modification of LDL was thought to play a key role in the initiation and progression of atherosclerosis, efonidipine hydrochloride may be useful against atherosclerosis. [Journal Article; In Japanese; Japan]

CAS Registry Numbers: Calcium Channel Blockers; Dihydropyridines; Lipoproteins, LDL; Nitrophenols; Organophosphorus Compounds; 111011-53-1, efonidipine; 63675-72-9, Nisoldipine

Citation Subset Indicators: Index Medicus

MeSH Terms: Animals; Arteriosclerosis, etiology (ET), prevention & control (PC); Calcium

Channel Blockers, * pharmacology (PD); Cells, Cultured; Depression, Chemical;
Dihydropyridines, * pharmacology (PD); Dose-Response Relationship, Drug; Endothelium,
cytology (CY), metabolism (ME); English Abstract; Lipoproteins, LDL, drug effects (DE), *
metabolism (ME); Male; Nisoldipine, pharmacology (PD); * Nitrophenols;
Organophosphorus Compounds, * pharmacology (PD); Rats; Rats, Wistar

**Nippon Yakurigaku Zasshi. Japanese Journal Of
Pharmacology**

Volume 106, Issue 4 , October 1995, Pages 263-270

ISSN: 0015-5691

This Document

► **Abstract-MEDLINE**

Actions

- [Cited By](#)
- [Save as Citation Alert](#)
- [E-mail Article](#)
- [Export Citation](#)

◀ results list

◀ previous

7 of 32

next ▶

[Home](#)

[Search](#)

[Journals](#)

[Books](#)

[Abstract Databases](#)

[My Profile](#)

[Alerts](#)

[? Help](#)

[Feedback](#) | [Terms & Conditions](#) | [Privacy Policy](#)

Copyright © 2005 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.



32 Articles Found

TITLE-ABSTR-KEY(efonidipine) and TITLE-ABSTR-KEY(nz)

[Edit Search](#) | [Save Search](#) | [Save as Search Alert](#)View: [Citations](#)Sort By: [Date](#)

1. ☐ **Effects of the antihypertensive drug efonidipine hydrochloride on albuminuria and renal histopathology in young spontaneously hypertensive rats with diabetes**
General Pharmacology, Volume 30, Issue 5, May 1998, Pages 749-752
Takeda, M; Shou, I; Tomino, Y
[Abstract-MEDLINE](#)
2. ☐ **Effects of the Antihypertensive Drug Efonidipine Hydrochloride on Albuminuria and Renal Histopathology in Young Spontaneously Hypertensive Rats with Diabetes • ARTICLE**
General Pharmacology, Volume 30, Issue 5, May 1998, Pages 749-752
Masahiro Takeda, Ichiyu Shou and Yasuhiko Tomino
[Abstract](#)
3. ☐ **Effects of efonidipine hydrochloride, a calcium antagonist derived from dihydropyridine, on acute myocardial ischemia in anesthetized open-chest dogs**
Nippon Yakurigaku Zasshi. Japanese Journal Of Pharmacology, Volume 108, Issue 6, December 1996, Pages 307-321
Yokoyama, T; Fujikura, N; Masuda, Y; Shikada, K; Tanaka, S
[Abstract-MEDLINE](#)
4. ☐ **Effect of efonidipine hydrochloride (NZ-105), a dihydropyridine derivative with calcium antagonistic action, on myocardial oxygen tension in anesthetized dogs**
Nippon Yakurigaku Zasshi. Japanese Journal Of Pharmacology, Volume 108, Issue 5, November 1996, Pages 267-274
Fujikura, N; Yokoyama, T; Masuda, Y; Shikada, K; Tanaka, S
[Abstract-MEDLINE](#)
5. ☐ **Effects of efonidipine, nicardipine and captopril on proteinuria in aged spontaneously hypertensive rats**
Arzneimittel-Forschung, Volume 46, Issue 9, September 1996, Pages 852-854
Shudo, C; Masuda, Y; Sugita, H; Tamura, T; Furukawa, S; Hayashi, K; Hirata, H; Shikada, K; Tanaka, S; Tomita *et al.*
[Abstract-MEDLINE](#)

6. ☐ **Effects of the new calcium antagonist efonidipine hydrochloride on resting and exercise hemodynamics in patients with stable effort angina**
Arzneimittel-Forschung, Volume 46, Issue 9, September 1996, Pages 861-867
Saito, T; Fujii, K; Takizawa, T; Toyosaki, T; Kuwabara, Y; Kobayashi, S; Ichikawa, H; Karaki, A; Yamazaki, Y; Iwata *et al.*
[Abstract-MEDLINE](#)
-
7. ☐ **Effect of efonidipine hydrochloride (NZ-105) on modification of low density lipoprotein induced by rat cultured endothelial cells**
Nippon Yakurigaku Zasshi. Japanese Journal Of Pharmacology, Volume 106, Issue 4, October 1995, Pages 263-270
Ito, S; Higashino, R; Tanaka, T; Takei, M; Kurimoto, T; Matsuda, K
[Abstract-MEDLINE](#)
-
8. ☐ **Identification of efonidipine hydrochloride metabolites in rats**
Arzneimittel-Forschung, Volume 45, Issue 7, July 1995, Pages 766-770
Nakabeppu, H; Nakajima, A; Kamikawaji, Y; Shinozaki, Y
[Abstract-MEDLINE](#)
-
9. ☐ **Effects of efonidipine hydrochloride (NZ-105), a calcium antagonist, on renal function in conscious spontaneously hypertensive rats**
General Pharmacology, Volume 26, Issue 2, March 1995, Pages 333-337
Yotsumoto, T; Masuda, Y; Shudo, C; Sugita, H; Yamashita, T; Tanaka, S
[Abstract-MEDLINE](#)
-
10. ☐ **Cardiovascular selectivity of 1,4-dihydropyridine derivatives, efonidipine (NZ-105), nicardipine and structure related compounds in isolated guinea-pig tissues**
General Pharmacology, Volume 26, Issue 2, March 1995, Pages 339-345
Masuda, Y; Miyajima, M; Shudo, C; Tanaka, S; Shigenobu, K; Kasuya, Y
[Abstract-MEDLINE](#)
-
11. ☐ **Effects of Efonidipine Hydrochloride (NZ-105), a Calcium Antagonist, on Renal Function in Conscious Spontaneously Hypertensive Rats • ARTICLE**
General Pharmacology, Volume 26, Issue 2, March 1995, Pages 333-337
T. Yotsumoto, Y. Masuda, C. Shudo, H. Sugita, T. Yamashita and S. Tanaka
[Abstract](#)
-
12. ☐ **Cardiovascular Selectivity of 1,4-Dihydropyridine Derivatives, Efonidipine (NZ-105), Nicardipine and Structure Related Compounds in Isolated Guinea-pig Tissues • ARTICLE**
General Pharmacology, Volume 26, Issue 2, March 1995, Pages 339-345
Y. Masuda, M. Miyajima, C. Shudo, S. Tanaka, K. Shigenobu and Y. Kasuya
[Abstract](#)
-
13. ☐ **Renal protective effect of efonidipine hydrochloride (NZ-105), a new calcium antagonist, in spontaneously hypertensive rats**
General Pharmacology, Volume 25, Issue 8, December 1994, Pages 1567-1575
Shudo, C; Masuda, Y; Sugita, H; Furukawa, S; Hayashi, K; Hirata, H; Tanaka, S; Tomita, K

14. ☐ **Renal protective effect of efonidipine hydrochloride (NZ-105), a new calcium antagonist, in spontaneously hypertensive rats • ARTICLE**
General Pharmacology: The Vascular System, Volume 25, Issue 8, December 1994, Pages 1567-1575
C. Shudo, Y. Masuda, H. Sugita, S. Furukawa, K. Hayashi, H. Hirata, S. Tanaka and K. Tomita
Abstract
-
15. ☐ **Effects of efonidipine hydrochloride (NZ-105), a new calcium antagonist, against acute renal failure in rats**
General Pharmacology, Volume 25, Issue 7, November 1994, Pages 1451-1458
Shudo, C; Masuda, Y; Sugita, H; Tanaka, S; Tomita, K
Abstract-MEDLINE
-
16. ☐ **Effects of efonidipine hydrochloride (NZ-105), a new calcium antagonist, against acute renal failure in rats • ARTICLE**
General Pharmacology: The Vascular System, Volume 25, Issue 7, November 1994, Pages 1451-1458
C. Shudo, Y. Masuda, H. Sugita, S. Tanaka and K. Tomita
Abstract
-
17. ☐ **Inhibitory effects of calcium antagonists on mitochondrial swelling induced by lipid peroxidation or arachidonic acid in the rat brain in vitro**
Neurochemical Research, Volume 19, Issue 9, September 1994, Pages 1199-1206
Takei, M; Hiramatsu, M; Mori, A
Abstract-MEDLINE
-
18. ☐ **Effects of a newly synthesized dihydropyridine, NZ-105, on intracellular Ca transients and tension in ferret ventricular muscles**
Journal Of Cardiovascular Pharmacology, Volume 24, Issue 2, August 1994, Pages 274-280
Kurihara, S; Hongo, K; Tanaka, T; Tanaka, E
Abstract-MEDLINE
-
19. ☐ **Effect of efonidipine hydrochloride (NZ-105), a new dihydropyridine calcium antagonist, on the experimental atherosclerosis in cholesterol-fed rabbits**
Nippon Yakurigaku Zasshi. Japanese Journal Of Pharmacology, Volume 103, Issue 5, May 1994, Pages 231-239
Toyoda, K; Kitahara, M; Yamashita, T; Shudo, C; Masuda, Y; Sakashita, M; Tanaka, S; Saito, Y
Abstract-MEDLINE
-
20. ☐ **Effects of long-term oral administration of NZ-105, a novel calcium antagonist, with or without propranolol in spontaneously hypertensive rats**
The Journal Of Pharmacy And Pharmacology, Volume 45, Issue 6, June 1993, Pages 525-529
Shudo, C; Masuda, Y; Sakai, T; Tanaka, S; Shigenobu, K; Kasuya, Y

21. ☐ **Inhibitory effect of NZ-105, a 1,4-dihydropyridine derivative, on cyclic nucleotide phosphodiesterase activity**
The Journal Of Pharmacy And Pharmacology, Volume 45, Issue 6, June 1993, Pages 530-534
Yamashita, T; Masuda, Y; Sakai, T; Tanaka, S; Kasuya, Y
Abstract-MEDLINE
-
22. ☐ **Studies on the hypotensive mechanisms of NZ-105, a new dihydropyridine derivative, in rats and rabbits**
General Pharmacology, Volume 24, Issue 2, March 1993, Pages 411-418
Shudo, C; Masuda, Y; Sakai, T; Tanaka, S; Shigenobu, K; Kasuya, Y
Abstract-MEDLINE
-
23. ☐ **Synthesis of 1,4-dihydropyridine-5-phosphonates and their calcium-antagonistic and antihypertensive activities: novel calcium-antagonist 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate hydrochloride ethanol (NZ-105) and its crystal structure**
Chemical & Pharmaceutical Bulletin, Volume 40, Issue 9, September 1992, Pages 2362-2369
Sakoda, R; Kamikawaji, Y; Seto, K
Abstract-MEDLINE
-
24. ☐ **Synthesis and crystal structure of optically active 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate (NZ-105)**
Chemical & Pharmaceutical Bulletin, Volume 40, Issue 9, September 1992, Pages 2377-2381
Sakoda, R; Matsumoto, H; Seto, K
Abstract-MEDLINE
-
25. ☐ **Affinity of Z-105 to the 1,4-dihydropyridine type calcium channel and several other receptor bindings in the central nervous system**
Nippon Yakurigaku Zasshi. Japanese Journal Of Pharmacology, Volume 100, Issue 1, July 1992, Pages 59-66
Niwa, M; Nozaki, M; Kobayashi, M; Tsurumi, K
Abstract-MEDLINE
-
26. ☐ **Effects of NZ-105, a new calcium antagonist, on renal function in anesthetized spontaneously hypertensive rats**
Journal Of Cardiovascular Pharmacology, Volume 19, Issue 6, June 1992, Pages 851-856
Yokoyama, T; Masuda, Y; Sakai, T; Tanaka, S; Tomita, K
Abstract-MEDLINE
-
27. ☐ **Antihypertensive effects and pharmacokinetics of NZ-105 single administration in patients with hypertension**
Nippon Jinzo Gakkai Shi, Volume 34, Issue 2, February 1992, Pages 199-205

Yokoyama, S; Kaburagi, T; Mori, N; Sakata, K; Yoshida, H; Hoshino, T
[Abstract-MEDLINE](#)

-
28. ☐ **NZ-105, a new 1,4-dihydropyridine derivative: correlation between dihydropyridine receptor binding and inhibition of calcium uptake in rabbit aorta**
Japanese Journal Of Pharmacology, Volume 57, Issue 3, November 1991, Pages 337-348
Yamashita, T; Masuda, Y; Sakai, T; Tanaka, S; Kasuya, Y
[Abstract-MEDLINE](#)
-
29. ☐ **Cardiac and vascular effects of NZ-105, a novel dihydropyridine derivative, in vitro**
Archives Internationales De Pharmacodynamie Et De Therapie, Volume 314, November - December 1991, Pages 57-73
Masuda, Y; Iwama, T; Yamashita, T; Sakai, T; Hibi, M; Tanaka, S; Shigenobu, K; Kasuya, Y
[Abstract-MEDLINE](#)
-
30. ☐ **Vasorelaxing and receptor binding properties of NZ-105, a novel dihydropyridine derivative, in isolated rabbit aorta**
Archives Internationales De Pharmacodynamie Et De Therapie, Volume 312, July - August 1991, Pages 86-103
Masuda, Y; Iwama, T; Yamashita, T; Sakai, T; Hibi, M; Tanaka, S; Shigenobu, K; Kasuya, Y
[Abstract-MEDLINE](#)
-
31. ☐ **Mechanisms underlying the slow onset of action of a new dihydropyridine, NZ-105, on a cultured smooth muscle cell line**
Naunyn-Schmiedeberg's Archives Of Pharmacology, Volume 343, Issue 4, April 1991, Pages 405-410
Tamura, T; Saigusa, A; Kokubun, S
[Abstract-MEDLINE](#)
-
32. ☐ **Antihypertensive and diuretic effects of NZ-105, a novel dihydropyridine derivative**
Archives Internationales De Pharmacodynamie Et De Therapie, Volume 304, March - April 1990, Pages 247-264
Masuda, Y; Takeguchi, M; Arakawa, C; Sakai, T; Hibi, M; Tanaka, S; Shigenobu, K; Kasuya, Y
[Abstract-MEDLINE](#)
-

32 Articles Found

TITLE-ABSTR-KEY(efonidipine) and TITLE-ABSTR-KEY(nz)

[Edit Search](#) | [Save Search](#) | [Save as Search Alert](#)

results 1 - 32

[Home](#) [Search](#) [Journals](#) [Books](#) [Abstract Databases](#) [My Profile](#) [Alerts](#)

[? Help](#)

[Feedback](#) | [Terms & Conditions](#) | [Privacy Policy](#)

Copyright © 2005 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.